

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) ~~Composition of lipophilic molecules that can be diffused in aqueous medium, characterized in that it comprises at least one derivative of the aryl-carboxylic family and/or a lipophilic anti-inflammatory and/or a lipophilic anti-mycotic and/or a lipophilic analgesic of the morphine type and/or a lipophilic anti-allergic, in the form of salts of these molecules~~ A composition to be administered as a tablet or lozenge, comprising a low dosage lipophilic non-steroidal anti-inflammatory (NSAID) or anti-mycotic drug under an amino acid salt form, wherein the composition can be passively diffused into buccal and throat mucous membranes when the composition is totally released, dissolved, coated to the mucous membrane, and then absorbed through mucous.

2. (currently amended) ~~Composition of lipophilic molecules~~ The composition according to claim 1, ~~wherein the molecule is a derivative of the aryl-carboxylic family combined with~~ comprising a substrate that makes possible a slow permucosal

diffusion that is uniform and localized to the buccopharyngeal cavity.

3. (currently amended) ~~Composition~~ The composition according to claim 1, wherein at least one ~~derivative of the aryl-carboxylic family and/or the lipophilic anti-inflammatory and/or the lipophilic antimycotic and/or the lipophilic analgesic of the morphine type and/or the lipophilic anti-allergic lipophilic non-steroidal anti-inflammatory drug (NSAID) and/or at least one lipophilic anti-mycotic drug~~ is combined with at least one amino acid.

4. (currently amended) ~~Composition~~ The composition according to claim 3, wherein the amino acid ~~that is retained~~ is lysine, arginine, or histidine.

5. (currently amended) ~~Composition~~ The composition according to claim 1, ~~wherein it comprises~~ comprising a polymer agent that is ~~selected from among the family of a cellulose derivative~~ derivatives, ~~more particularly carboxy methyl cellulose that contains soda, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose or promellose, or carboxy methyl cellulose.~~

6. (currently amended) ~~Composition~~ The composition according to claim 1, ~~wherein it comprises~~ comprising a polymer

agent that is a gum ~~selected from among the family of gums, such as guar gum, gum Arabic, or xanthane gum.~~

7. (currently amended) ~~Composition~~ The composition ~~for the treatment of buccopharyngeal ailments~~ according to claim 1, ~~wherein it comprises~~ comprising a polymer agent that is selected from ~~among the compounds:~~ alginic acid and derivatives, carboxy-vinyl polymer, carbomer, macrogols, polyethylene glycols, gelatin, povidone, ~~or~~ and pectins.

8. (currently amended) ~~Composition for the treatment of buccopharyngeal ailments~~ The composition according to claim 1, ~~wherein it comprises a~~ comprising a carbohydrate substrate ~~that is selected from among the carbohydrates, more particularly lactose, glucose, saccharose, sorbitol, mannitol or xylitol.~~

9. (currently amended) ~~Tablet including~~ A low dosage tablet comprising the composition according to claim 1, ~~wherein it comprises~~ having the following formulation:

- | | |
|-----------------------|-------|
| - ibuprofen lysinate: | 25 mg |
| - magnesium stearate: | 10 mg |
| - talc: | 50 mg |
| - aspartame: | 15 mg |

- ~~metolose~~
hydroxy-propyl-methyl
cellulose: 70 mg
- Arome: 20 mg
- sorbitol: 810 mg

10. (currently amended) ~~Tablet including~~ A low dosage
tablet comprising the composition according to claim 1, ~~wherein it~~
~~comprises~~ having the following formulation:

- ketoprofen lysinate: 5 mg
- magnesium stearate: 10 mg
- talc: 50 mg
- aspartame: 15 mg
- ~~metolose~~
hydroxy-propyl-methyl
cellulose: 70 mg
- Arome: 20 mg
- sorbitol: 830 mg

11-12. (cancelled)

13. (currently amended) ~~Composition~~ The composition
according to claim 2, wherein at least one ~~derivative of the~~
~~aryl carboxylic family and/or the lipophilic anti inflammatory~~
~~and/or the lipophilic antimycotic and/or the lipophilic analgesic~~

~~of the morphine type and/or the lipophilic anti-allergic~~
lipophilic non-steroidal anti-inflammatory drug and/or at least one
lipophilic anti-mycotic drug is combined with at least one amino
acid.

14. (currently amended) ~~Composition~~ The composition
according to claim 2, ~~wherein it comprises~~ comprising a polymer
agent that is ~~selected from among the family of a cellulose~~
derivative ~~derivatives, more particularly carboxy methyl cellulose~~
~~that contains soda, hydroxy ethyl cellulose, hydroxy propyl~~
~~cellulose, hydroxy propyl methyl cellulose or promellose, or~~
~~carboxy methyl cellulose.~~

15. (currently amended) ~~Composition~~ The composition
according to claim 3, ~~wherein it comprises~~ comprising a polymer
agent that is ~~selected from among the family of a cellulose~~
derivative ~~derivatives, more particularly carboxy methyl cellulose~~
~~that contains soda, hydroxy ethyl cellulose, hydroxy propyl~~
~~cellulose, hydroxy propyl methyl cellulose or promellose, or~~
~~carboxy methyl cellulose.~~

16. (currently amended) ~~Composition~~ The composition
according to claim 4, ~~wherein it comprises~~ comprising a polymer
agent that is ~~selected from among the family of a cellulose~~
derivative ~~derivatives, more particularly carboxy methyl cellulose~~

~~that contains soda, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose or promellose, or carboxy methyl cellulose.~~

17. (currently amended) ~~Composition~~ The composition according to claim 2, ~~wherein it comprises~~ comprising a polymer agent that is a gum ~~selected from among the family of gums, such as guar gum, gum Arabic, or xanthane gum.~~

18. (currently amended) ~~Composition~~ The composition according to claim 3, ~~wherein it comprises~~ comprising a polymer agent that is a gum ~~selected from among the family of gums, such as guar gum, gum Arabic, or xanthane gum.~~

19. (currently amended) ~~Composition~~ The composition according to claim 4, ~~wherein it comprises~~ comprising a polymer agent that is a gum ~~selected from among the family of gums, such as guar gum, gum Arabic, or xanthane gum.~~

20. (currently amended) ~~Composition~~ The composition according to claim 5, ~~wherein it comprises~~ comprising a polymer agent that is a gum ~~selected from among the family of gums, such as guar gum, gum Arabic, or xanthane gum.~~

21. (new) A method for producing a medication for treating buccopharyngeal ailments by local permucosal diffusion, comprising providing the composition according to claim 2, and including the composition in the medication.

22. (new) A method for treating buccopharyngeal ailments by local permucosal diffusion comprising administering the tablet according to claim 9 to a subject in need thereof.

23. (new) The composition according to claim 5, wherein the cellulose derivative is carboxy-methyl cellulose that contains soda, hydroxy-ethyl cellulose, hydroxy-propyl cellulose, hydroxy-propyl methyl cellulose or promellose, or carboxy-methyl cellulose.

24. (new) The composition according to claim 6, wherein the gum is guar gum, gum Arabic, or xanthane gum.